Brand-Name Rituximab Will Get FDA Priority Review for a New Pediatric Indication – The Center for Biosimilars

Brand-Name Rituximab Will Get FDA Priority Review for a New Pediatric Indication – The Center for Biosimilars

Brand-Name Rituximab Will Get FDA Priority Review for a New Pediatric Indication – The Center for Biosimilars
Published on 2019-06-13